Navigation Links
Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
Date:9/10/2007

Results Demonstrate that NKTR-118 Shows Promise for the Treatment of Opioid

Bowel Dysfunction

SAN CARLOS, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented results today at the American College of Clinical Pharmacology conference in San Francisco, California from a Phase 1 trial of NKTR-118 (oral PEG-naloxol). NKTR-118 is Nektar's proprietary investigational treatment for opioid bowel dysfunction (OBD), including opioid-induced constipation (OIC). Today's presentation highlights the safety profile and activity of NKTR-118 in healthy male subjects.

"This proof-of-principle study in combination with our preclinical work shows that our proprietary PEGylation technology can prevent an oral drug from penetrating the blood-brain barrier, opening the door for future applications of our technology with other small molecules," said Hoyoung Huh, M.D., Ph.D., Nektar's Chief Operating Officer and Head of the PEGylation Business Unit. "These findings for NKTR-118 merit further clinical evaluation of the drug. We look forward to unveiling the results of our multi-dose Phase 1 safety trial on NKTR-118 later this year and advancing this important program into Phase 2 clinical development."

The NKTR-118 Phase 1 results demonstrate that single oral doses of NKTR-118 reverse the effects of morphine on gastrointestinal transit time at doses that do not reverse a central opiate effect as measured by pupillometry.

Phase 1 Clinical Study Design

This single-dose, double-blind, placebo-controlled study was conducted to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic profile of NKTR-118 in healthy male subjects. The trial measure
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NimbleGen presents new tech for comparing microbe DNA
2. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
3. Thieme Presents Unique Technology Angle at Gov.s Conference
4. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
5. Housekeeping Genes: Universal Positive Controls in siRNA Knockdown Experiments
6. Analysis of Nitrofurans Metabolites by Positive Ion Electrospray LC/MS/MS
7. Rapid Screening of Amphetamine Drugs in Urine by Positive Ion Electrospray LC/MS/MS
8. Sonic Foundry reports first cash-positive quarter
9. Theres a surprising, and positive, side to the offshore jobs debate
10. Effects of Thermal Cycler Well-To-Well Temperature Uniformity on PCR Results
11. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... WABC Radio show out of New York City, ... will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, Robert ... pets. Dr. Harman first visited the show in November ... pets suffering from osteoarthritis and other degenerative diseases, as well ... , Young has invited Dr. Harman back to dial down ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/25/2014)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... , today announced that it will release its unaudited financial ... market close on Thursday, August 14, 2014 EDT. The Company ... on Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, ... review the Company,s financial results and provide an update on ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3
... China Yingxia,International, Inc. (OTC Bulletin Board: CYXI) ("China ... health and nutritional food industry,engaged in the development, ... and raw cactus plants in the People,s,Republic of ... Mr. Ren,Hu will present at the upcoming Roth ...
... Uroplasty, Inc. (Amex:,UPI) announced today that it will ... on Monday, November 10, 2008 at the New York,Palace ... Chief Executive,Officer and Medi Jiwani, Vice President and Chief ... financial,performance at 4:55 p.m. Eastern Time., Attendance at ...
... in medicine. Although no significant achievements for curing disease have been achieved, ... approaches. By the year 2015, global market for gene therapy is projected ... ... 2008 -- Advancements in gene therapy have provided useful data, which has ...
Cached Biology Technology:China Yingxia to Present at Roth China Comes to Vegas Conference 2Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York 2World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc. 2World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc. 3
(Date:7/27/2014)... studies to date, researchers from the U.K. provide national, ... C virus (HCV). Findings published in Hepatology, a journal ... Diseases, indicate that genotype 1 is the most prevalent ... one-third reside in East Asia. Genotype 3, at just ... followed by genotypes 2, 4, 6, and 5. ...
(Date:7/27/2014)... like bacteria and fungi can evade treatment by acquiring ... drugs. These permanent mutations were once thought to be ... a new study has shown that microorganisms can use ... epimutations -- to gain the benefits of drug resistance ... discovered in a fungus called Mucor circinelloides, it is ...
(Date:7/27/2014)... scientists at Barts Cancer Institute have found that targeting ... significantly more effective, according to research published in ... Institute, part of Queen Mary University of London, have ... signals the body to repair itself after chemotherapy or ... the researchers removed FAK from blood vessels that grew ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2
... the AIDS virus,s protein envelope once considered an improbable target ... most promising, new research by Dana-Farber Cancer Institute scientists indicates. ... the V3 loop, is an attractive vaccine target because immune ... multiple genetic subtypes of HIV-1, the virus that causes AIDS. ...
... "skin" of most every cell in your body, but the ... be rendered by many experimental techniques. A team of scientists ... and University of California, Irvine, recently developed a way to ... role of cholesterol within this boundary between the cell and ...
... Minnesota finalized a license agreement for CaSTT (Commerce and ... for technology transfer offices in universities and research institutions. ... consulting services that allow technology transfer offices to make ... and, in some cases, execute licenses from start to ...
Cached Biology News:Study identifies promising target for AIDS vaccine 2Study identifies promising target for AIDS vaccine 3Closer look at cell membrane shows cholesterol 'keeping order' 2